Next-generation cell therapies: the emerging role of CAR-NK cells

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy

(2020) Aline Pfefferle et al.   Cancers

Manufacturing chimeric antigen receptor T cells: issues and challenges

(2019) Claire Roddie et al.   CYTOTHERAPY

Clearance of hematological malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions

(2019) Michael Merker et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Updates on CAR T-cell therapy in B-cell malignancies

(2019) Elad Jacoby et al.   IMMUNOLOGICAL REVIEWS

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

(2019) Ramona Rotolo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering

(2018) May Daher et al.   CURRENT OPINION IN IMMUNOLOGY

Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia

(2018) Chiara F. Magnani et al.   HUMAN GENE THERAPY

Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).

(2018) Tanya Siddiqi et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

The CRISPR tool kit for genome editing and beyond

(2018) Mazhar Adli   Nature Communications

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells

(2018) V. Leuci et al.   OncoImmunology

A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

(2018) Christopher A. Vakulskas et al.   NATURE MEDICINE

Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays

(2018) Morito Kurata et al.   PLoS One

CRISPR-Cas guides the future of genetic engineering

(2018) Gavin J. Knott et al.   SCIENCE

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Natural Killer Cells: Development, Maturation, and Clinical Utilization

(2018) Alex M. Abel et al.   Frontiers in Immunology

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic CAR-T Cells: More than Ease of Access?

(2018) Charlotte Graham et al.   Cells

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective

(2017) Isabelle Rivière et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets

(2017) Shengdar Q Tsai et al.   NATURE METHODS

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

(2017) Elizabeth S. Allen et al.   TRANSFUSION

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children

(2017) Michael Merker et al.   Oncotarget

5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells

(2017) Xueyang Guo et al.   Scientific Reports

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival

(2016) Sarah Oelsner et al.   INTERNATIONAL JOURNAL OF CANCER

Genome-editing Technologies for Gene and Cell Therapy

(2016) Morgan L Maeder et al.   MOLECULAR THERAPY

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

(2015) Garnet Suck et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human gamma delta T cells: Evolution and ligand recognition

(2015) Erin J. Adams et al.   CELLULAR IMMUNOLOGY

Challenges and opportunities of allogeneic donor-derived CAR T cells

(2015) Yinmeng Yang et al.   CURRENT OPINION IN HEMATOLOGY

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

(2015) Xiao-Hui Zhang et al.   Molecular Therapy-Nucleic Acids

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications

(2015) Mattias Carlsten et al.   Frontiers in Immunology

CRISPR/Cas9 for genome editing: progress, implications and challenges

(2014) F. Zhang et al.   HUMAN MOLECULAR GENETICS

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

(2014) Shengdar Q Tsai et al.   NATURE BIOTECHNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Follicular lymphoma with leukemic phase at diagnosis: A series of seven cases and review of the literature

(2013) Brady E. Beltran et al.   LEUKEMIA RESEARCH

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

(2013) David A. Knorr et al.   Stem Cells Translational Medicine

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

(2012) M. Jinek et al.   SCIENCE

Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity

(2011) A. Pievani et al.   BLOOD

RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers

(2011) Joseph R Dobosy et al.   BMC BIOTECHNOLOGY

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

Use of allogeneic NK cells for cancer immunotherapy

(2011) Melissa A Geller et al.   Immunotherapy